Clinical Trial Update: Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating niraparib in combination with dostarlimab for germline or somatic BRCA1/2 and PALB2-mutated metastatic pancreatic cancer has completed.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)
• Zejula (Niraparib)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Status: COMPLETED | Results posted: 2025-08-07